Preprint Review Version 1 This version not peer reviewed

Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting

Version 1 : Received: 8 February 2018 / Approved: 9 February 2018 / Online: 9 February 2018 (10:37:33 CET)

How to cite: Sonvico, F.; Clementino, A.R.; Buttini, F.; Colombo, G.; Pescina, S.; Stanisçuaski Guterres, S.; Raffin Pohlmann, A.; Nicoli, S. Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting. Preprints 2018, 2018020077 (doi: 10.20944/preprints201802.0077.v1). Sonvico, F.; Clementino, A.R.; Buttini, F.; Colombo, G.; Pescina, S.; Stanisçuaski Guterres, S.; Raffin Pohlmann, A.; Nicoli, S. Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting. Preprints 2018, 2018020077 (doi: 10.20944/preprints201802.0077.v1).

Abstract

In the field of nasal delivery, one of the most fascinating applications is the delivery of drugs directly to the central nervous system bypassing the blood brain barrier. This approach would provide a series of benefits, such as dose lowering and direct targeting of potent drugs, ultimately reducing their systemic side effects. Recently, clinical trials have explored the nasal administration of insulin for the treatment of Alzheimer’s disease, with promising results. The use of nanomedicines could provide further options for making nose-to-brain delivery reality. In particular, apart from the selection of devices able to deposit the formulation in the upper part of the nose, surface modification of these nanomedicines appears the key strategy to optimize the delivery of drugs from the nasal cavity to the brain. In this review, nanomedicines delivery approaches based on surface electrostatic charges, mucoadhesive polymers, as well as chemical moieties targeting nasal epithelium, will be discussed and critically evaluated for nose-to-brain delivery.

Subject Areas

nose to brain delivery; nanoparticles; pharmaceutical nanotechnology; mucoadhesion; mucus penetrating particles; targeting; CNS disorders; neurodegenerative diseases; Alzheimer’s disease; Parkinson’s disease

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.